References
- Anderson FA Jr, Zayaruzny M, Heit JA, et al. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007;82:777-82
- Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98:756-64
- Spyropoulos A, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86
- Levy E, Gabriel S, Dinet J, et al. Assessing the total cost of management of a patient with deep vein thrombosis (DVT) in France and Italy. Value Health 2001;4:102
- Oster G, Ollendorf DA, Vera-Llonch M, et al. Economic consequences of venous thromboembolism following major orthopedic surgery. Ann Pharmacother 2004;38:377-82
- Merli G. Improving venous thromboembolism performance: a comprehensive guide for physicians and hospitalists. Hosp Pract (Minneap) 2010;38:7-16
- Bayer Inc. Xarelto (rivaroxaban) Product Monograph. 2008. Available at: http://www.bayer.ca/files/XARELTO-PM-ENG-10SEP2008-119111.pdf [Last accessed 2 February 2011]
- Bayer Schering Pharma AG. Xarelto® (rivaroxaban) Summary of Product Characteristics. 2009. Available at: http://www.xarelto.com/html/downloads/Xarelto_Summary_of_Product_Characteristics_May2009.pdf [Last accessed 2 February 2011]
- Boehringer Ingelheim International GmbH. Pradaxa (dabigatran etexilate) Summary of Product Characteristics. 2010. Available at: http://www.medicines.org.uk/emc/medicine/20760 [Last accessed 2 February 2011]
- Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
- National Institute for Health and Clinical Excellence. Briefing paper for methods review workshop on evidence synthesis (indirect and mixed treatment comparisons). 2007. Available at: http://www.nice.org.uk/media/4A6/2F/EvidenceSynthesisBriefingPaper.pdf [Last accessed 2 February 2011]
- Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75
- Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9
- Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86
- Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-80
- Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85
- Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56
- The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9
- Johnson & Johnson Pharmaceutical Research & Development LLC. Advisory committee briefing book. Rivaroxaban for the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery. 2009. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM138385.pdf [Last accessed 2 February 2011]
- Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007;89:799-807
- Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134
- Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edn). Chest 2008;133:381-453S
- Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croat Med J 2010;51:113-23
- Loke YK, Kwok C. Dabigatran and rivaroxaban for prevention of venous thromboembolism -- systematic review and adjusted indirect comparison. J Clin Pharm Ther 2010;35:1-14